Antitumour metal compounds: more than theme and variations

Triggered by the resounding success of cisplatin, the past decades have seen tremendous efforts to produce clinically beneficial analogues. The recent achievement of oxaliplatin for the treatment of colon cancer should, however, not belie the imbalance between a plethora of investigated complexes an...

Full description

Saved in:
Bibliographic Details
Published in:Dalton transactions : an international journal of inorganic chemistry 2008-01 (2), p.183-194
Main Authors: Jakupec, Michael A, Galanski, Markus, Arion, Vladimir B, Hartinger, Christian G, Keppler, Bernhard K
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - pharmacology
Gallium - pharmacology
Humans
Ligands
Organometallic Compounds - pharmacology
Organoplatinum Compounds - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Triggered by the resounding success of cisplatin, the past decades have seen tremendous efforts to produce clinically beneficial analogues. The recent achievement of oxaliplatin for the treatment of colon cancer should, however, not belie the imbalance between a plethora of investigated complexes and a very small number of clinically approved platinum drugs. Strategies opening up new avenues are increasingly being sought using complexes of metals other than platinum such as ruthenium or gallium. Based on the chemical differences between these metals, the spectrum of molecular mechanisms of action and potential indications can be broadened substantially. Other approaches focus on complexes with tumour-targeting properties, thereby maximizing the impact on cancer cells and minimizing the problem of adverse side effects, and complexes with biologically active ligands.
ISSN:1477-9226
1477-9234
DOI:10.1039/b712656p